Heart failure is a harmful disease that is associated with high avoidable moribidity that can be treated with a cardiac resynchronization therapy device (CRT-D). Previous studies have shown links between CRT-D implants and reduced rates of morbidity in patients with heart failure with left bundle branch blockages (LBBB). However, there is limited amounts of evidence for the success of heart failure patients with non-LBBB. This prospective, multi-center study is looking at heart failure patients with non-LBBB that are implanted with CRT-D.
Search Tufts Medicine
Additional development of an enzyme called IgA protease as a means to remove IgA (a protein) from the kidney.
This study is looking at home cooking patterns in people seen at the Tufts GI clinic with IBD and those without IBD. Participants will be given a questionnaire that will ask about different parts of the participants' home cooking patterns including attitudes, self-efficacy, and knowledge. By taking the responses to the questionnaire, we plan to examine different variables linked to home cooking pattern and how they differ between people seen at the GI clinic here at Tufts with IBD, and people seen at the clinic without IBD.
Patients who need vision testing (acuity and fields) will be asked to be tested at home or at the bedside with the ViuALL device. They and their phyysicians will be asked about the advantages and disadvantages of the new device.
HIP ATTACK-2 is a multi-center, international, randomized controlled trial to determine whether accelerated surgery for hip fracture in patients with acute myocardial injury is superior to standard care in reducing death at 90 days after randomization. Other outcomes include; inability to walk 3 meters independently, time to standing and weight-bearing, delirium, length of stay, pain, and quality of life.
This is an open label, multicenter, single arm phase II study to evaluate the efficacy and safety of ribociclib and ET in patients with locoregional recurrence of HR-positive, HER2-negative breast cancer.
Mirvetuximab Soravtansine (MIRV) is an investigational antibody drug conjugate designed to selectively kill cancer cells. The antibody (protein) part of MIRV targets tumors by delivering a cell-killing drug to the tumor cells carrying a tumor-associated protein called folate receptor alpha (FRα). It is being developed as maintenance therapy for the treatment of subjects with recurrent platinum-sensitive, highgrade epithelial ovarian, primary peritoneal, or fallopian tube cancers with high folate receptor-alpha expression.
This is a Prospective, multicenter, randomized, parallel-controlled, open-label two arm trial with an adaptive design. Eligible subjects will be randomized in a 1:1 ratio to PCI with Impella CP® (Intervention Group) versus standard of care PCI with or without IABP (Control Group). Approximately 1252 subjects will be randomized in a 1:1 ratio to PCI + Impella vs. PCI ± IABP.
This prospective, single center, randomized, double-masked, parallel comparison, sponsored study seeks to investigate the efficacy of IDI on ameliorating the signs and symptoms of dry eye disease. The study aims to enroll 54 patients (36 Dextenza commercial formulation, 18 Collagen Plug) with DED.
This study seeks to obtain cancer and healthy tissue from women with metastatic ovarian cancer. The tissue will be used in a preclinical study to develop a multi-scale imaging probe that can better detect cancer metastases.
The aim of this study is to improve the metabolic health of overweight and obese women prior to a planned pregnancy.
The purpose of this study is to measure the effect of maternal diet and metabolism (how your body uses food for energy) on the growth of the baby, and how the placenta uses lipids.
Researchers at Tufts Medical Center are conducting a study on the benefits of mepivacaine in neuraxial anesthesia for certain neurosurgical procedures. The purpose of this study is to see if mepivacaine, a local anesthetic, can shorten your time in the recovery room/hospital; decrease the amount of time before you can walk after surgery; allow you to urinate sooner after surgery; and reduce any nausea and vomiting that you might experience after anesthesia and surgery.
This study will evaluate the safety and effectiveness outcomes of FRED X device in a population of patients that aligns with the indications for use of the FRED device. The data generated from this study will be compared to the safety and effectiveness of the FRED device by meeting the same performance goals established for the FRED pivotal study.
This is a pilot/feasibility study on the accuracy of HRV measured by the Apple Watch on the clinical status of patients admitted for acute heart failure decompnsation. We hypothesize that there will be a statistically significant improvement in the HRV that correlates clinically over the course of hospitalization. Meaningful findings from this study will strengthen the potential for a telemonitoring system where HRV measured remotely from home using wearable devices like Apple Watch can help physicians monitoring their health and intervene accordingly.
The MADIT S-ICD trial is designed to evaluate if subjects with a prior myocardial infarction, diabetes mellitus and a relatively preserved ejection fraction of 36-50% will have a survival benefit from receiving a subcutaneous implantable cardioverter defibrillator (S-ICD) when compared to those receiving conventional medical therapy.
Parallel-group, prospective, randomized, controlled phase III trial of home High flow Nasal Therapy (HFNT) via myAirvo 3 plus usual COPD medical care vs. usual COPD medical care, for at least 1 year and up to two years in 642 GOLD Grade E, Stages II-IV patients with moderate to very severe COPD at risk for moderate and severe exacerbations with a prior history of severe exacerbation requiring hospitalization within the past 6 weeks.
This patient registry aims to recruit people who have recovered following infection with SARS-CoV-2 / COVID-19 for the purpose of connecting them with researchers in the United States who are conducting research to learn about the survivor experience, and develop new treatments for patients currently with the illness.
- To establish the prevalence of neuropathic corneal pain in patients with ocular surface discomfort.
- To assess the overlap of neuropathic corneal pain with dry eye disease in patients in diseases that are currently thought to be mutually exclusive.
- To establish the prevalence of subtypes of patients with neuropathic corneal pain or with a neuropathic component of dry eye in patients with ocular surface discomfort.
This is a longitudinal observational study that will look at 300 subjects, 200 with intermediate AMD in at least one eye, or with AMD in one eye, either early or intermediate, and with late AMD (exudative) in the other eye, and 100 subjects with nGA or GA in at least one eye.
The target population is all subjects who are at least 50 years of age and have a clinical diagnosis of non-exudative AMD in at least one eye.